{"id":768741,"date":"2023-07-10T18:40:56","date_gmt":"2023-07-10T22:40:56","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/crinetics-pharmaceuticals-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-16\/"},"modified":"2023-07-10T18:40:56","modified_gmt":"2023-07-10T22:40:56","slug":"crinetics-pharmaceuticals-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-16","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/crinetics-pharmaceuticals-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-16\/","title":{"rendered":"Crinetics Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"left\">SAN DIEGO, July  10, 2023  (GLOBE NEWSWIRE) &#8212; <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=Vv2LDRNuweVcJpUPG5QKjdS6cQcDMCUdmXDS7IDy3LB7h34knVly6AWAUC1PVi7XXLg-IsOEk_yqjmg1X4yGeuDVno0yC9ppg8ivNlAA0_A=\" rel=\"nofollow noopener\" target=\"_blank\">Crinetics Pharmaceuticals, Inc.<\/a> (Nasdaq: CRNX), a clinical stage pharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors, today announced that on July 10, 2023,\u00a0the Compensation Committee of Crinetics\u2019 Board of Directors granted non-qualified stock option awards to purchase an aggregate of 323,600 shares of its common stock to 10 new non-executive employees under the Crinetics Pharmaceuticals, Inc. 2021 Employment Inducement Incentive Award Plan (the \u201c2021 Inducement Plan\u201d). The stock options were granted as inducements material to the employees entering into employment with Crinetics in accordance with Nasdaq Listing Rule 5635(c)(4).<\/p>\n<p>The 2021 Inducement Plan is used exclusively for the grant of equity awards to individuals who were not previously employees of Crinetics, or following a bona fide period of non-employment, as an inducement material to such individuals\u2019 entering into employment with Crinetics, pursuant to Nasdaq Listing Rule 5635(c)(4).<\/p>\n<p>The options have an exercise price of $19.75 per share, which is equal to the closing price of Crinetics\u2019 common stock on The Nasdaq Global Select Market on July 10, 2023. The shares subject to the stock options will vest over four years, with 25% of the shares vesting on the one-year anniversary of the applicable vesting commencement date and the balance of the shares vesting in a series of 36 successive equal monthly installments thereafter, subject to each employee\u2019s continued employment with Crinetics on such vesting dates. The options are subject to the terms and conditions of the 2021 Inducement Plan and the terms and conditions of a stock option agreement covering the grant.<\/p>\n<p align=\"justify\">\n        <strong>About Crinetics Pharmaceuticals<br \/><\/strong><br \/>\n        <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=Vv2LDRNuweVcJpUPG5QKjdS6cQcDMCUdmXDS7IDy3LAXplBT9cK6oPSzjqRU7c-69ahiFVfZJGIJ0ZQK05NrSEcovTn5KGlUib_tJZplWqM=\" rel=\"nofollow noopener\" target=\"_blank\">Crinetics Pharmaceuticals<\/a> is a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. Paltusotine, an investigational, oral somatostatin receptor type 2 (SST2) agonist, is in Phase 3 clinical development for acromegaly and Phase 2 clinical development for carcinoid syndrome associated with neuroendocrine tumors. Crinetics has demonstrated pharmacologic proof-of-concept in Phase 1 clinical studies for CRN04777, an investigational, oral somatostatin receptor type 5 (SST5) agonist in development for congenital hyperinsulinism, and for\u00a0CRN04894, an investigational, oral ACTH antagonist in development for the treatment of Cushing\u2019s disease, congenital adrenal hyperplasia, and other diseases of excess ACTH. All of the company\u2019s drug candidates are orally delivered, small molecule new chemical entities resulting from in-house drug discovery efforts.<\/p>\n<p>\n        <strong>Contacts:<\/strong><br \/>\n        <br \/>Chas Schultz<br \/>Vice President of IR and Corporate Communications<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=yl0HGdIB3UF7AHMWpVzK9klT-R-1mq22_tJRLaI-Q5lo0DY4XIx5m44oBHWiU6K-5ENHmZGgD8zyFGu-3vePDgxWKKKR7PWPvshyPpqT5o4=\" rel=\"nofollow noopener\" target=\"_blank\">cschultz@crinetics.com<\/a>\u00a0\u00a0 <br \/>(858) 450-6464<\/p>\n<p>\n        <strong>Investors \/ Media:<\/strong><br \/>\n        <br \/>Corey Davis<br \/>LifeSci Advisors, LLC<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=Hwzy0xKY9bdBO_dzJCfQg3_hcac58Th1n6D9Gfn6r7Oan7zvCoNCzDMkPTZ0oG8dr1x3cg2Md6rl9WHeUqF4Cpu4PmpRPm_hfWC5SCGY1KyIsd8WqbiiG5oh9EPwPC6Z\" rel=\"nofollow noopener\" target=\"_blank\">cdavis@lifesciadvisors.com<\/a><br \/>(212) 915-2577<\/p>\n<p>Aline Sherwood<br \/>Scienta Communications<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=Px7617rtWI0uRZI9EIIX1hhO_5oKT49NWfIy89Usd46UEAxmYj_84vQEUL9pQv4ToKWlHElSTWoQdxMq8Gfr5MVsBDYIV69Pm_SfuS07-fs=\" rel=\"nofollow noopener\" target=\"_blank\">asherwood@scientapr.com<\/a><br \/>(312) 238-8957<\/p>\n<p>      <img decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODg3MTkwMyM1NjgyMTEwIzIwODk4MTU=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" src=\"https:\/\/ml.globenewswire.com\/media\/NTJkNTY4NDEtZmM1Ny00ODNmLWI5MmItYTg1MGI3NDIzNDY5LTExMDEzODY=\/tiny\/Crinetics-Pharmaceuticals-Inc-.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>SAN DIEGO, July 10, 2023 (GLOBE NEWSWIRE) &#8212; Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical stage pharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors, today announced that on July 10, 2023,\u00a0the Compensation Committee of Crinetics\u2019 Board of Directors granted non-qualified stock option awards to purchase an aggregate of 323,600 shares of its common stock to 10 new non-executive employees under the Crinetics Pharmaceuticals, Inc. 2021 Employment Inducement Incentive Award Plan (the \u201c2021 Inducement Plan\u201d). The stock options were granted as inducements material to the employees entering into employment with Crinetics in accordance with Nasdaq Listing Rule 5635(c)(4). The 2021 Inducement Plan is used exclusively for the grant of equity &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/crinetics-pharmaceuticals-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-16\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Crinetics Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-768741","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Crinetics Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/crinetics-pharmaceuticals-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-16\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Crinetics Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"SAN DIEGO, July 10, 2023 (GLOBE NEWSWIRE) &#8212; Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical stage pharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors, today announced that on July 10, 2023,\u00a0the Compensation Committee of Crinetics\u2019 Board of Directors granted non-qualified stock option awards to purchase an aggregate of 323,600 shares of its common stock to 10 new non-executive employees under the Crinetics Pharmaceuticals, Inc. 2021 Employment Inducement Incentive Award Plan (the \u201c2021 Inducement Plan\u201d). The stock options were granted as inducements material to the employees entering into employment with Crinetics in accordance with Nasdaq Listing Rule 5635(c)(4). The 2021 Inducement Plan is used exclusively for the grant of equity &hellip; Continue reading &quot;Crinetics Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/crinetics-pharmaceuticals-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-16\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2023-07-10T22:40:56+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODg3MTkwMyM1NjgyMTEwIzIwODk4MTU=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/crinetics-pharmaceuticals-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-16\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/crinetics-pharmaceuticals-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-16\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Crinetics Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)\",\"datePublished\":\"2023-07-10T22:40:56+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/crinetics-pharmaceuticals-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-16\\\/\"},\"wordCount\":424,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/crinetics-pharmaceuticals-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-16\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODg3MTkwMyM1NjgyMTEwIzIwODk4MTU=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/crinetics-pharmaceuticals-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-16\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/crinetics-pharmaceuticals-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-16\\\/\",\"name\":\"Crinetics Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/crinetics-pharmaceuticals-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-16\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/crinetics-pharmaceuticals-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-16\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODg3MTkwMyM1NjgyMTEwIzIwODk4MTU=\",\"datePublished\":\"2023-07-10T22:40:56+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/crinetics-pharmaceuticals-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-16\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/crinetics-pharmaceuticals-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-16\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/crinetics-pharmaceuticals-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-16\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODg3MTkwMyM1NjgyMTEwIzIwODk4MTU=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODg3MTkwMyM1NjgyMTEwIzIwODk4MTU=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/crinetics-pharmaceuticals-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-16\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Crinetics Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Crinetics Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/crinetics-pharmaceuticals-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-16\/","og_locale":"en_US","og_type":"article","og_title":"Crinetics Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Market Newsdesk","og_description":"SAN DIEGO, July 10, 2023 (GLOBE NEWSWIRE) &#8212; Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical stage pharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors, today announced that on July 10, 2023,\u00a0the Compensation Committee of Crinetics\u2019 Board of Directors granted non-qualified stock option awards to purchase an aggregate of 323,600 shares of its common stock to 10 new non-executive employees under the Crinetics Pharmaceuticals, Inc. 2021 Employment Inducement Incentive Award Plan (the \u201c2021 Inducement Plan\u201d). The stock options were granted as inducements material to the employees entering into employment with Crinetics in accordance with Nasdaq Listing Rule 5635(c)(4). The 2021 Inducement Plan is used exclusively for the grant of equity &hellip; Continue reading \"Crinetics Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/crinetics-pharmaceuticals-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-16\/","og_site_name":"Market Newsdesk","article_published_time":"2023-07-10T22:40:56+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODg3MTkwMyM1NjgyMTEwIzIwODk4MTU=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/crinetics-pharmaceuticals-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-16\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/crinetics-pharmaceuticals-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-16\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Crinetics Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)","datePublished":"2023-07-10T22:40:56+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/crinetics-pharmaceuticals-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-16\/"},"wordCount":424,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/crinetics-pharmaceuticals-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-16\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODg3MTkwMyM1NjgyMTEwIzIwODk4MTU=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/crinetics-pharmaceuticals-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-16\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/crinetics-pharmaceuticals-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-16\/","name":"Crinetics Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/crinetics-pharmaceuticals-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-16\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/crinetics-pharmaceuticals-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-16\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODg3MTkwMyM1NjgyMTEwIzIwODk4MTU=","datePublished":"2023-07-10T22:40:56+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/crinetics-pharmaceuticals-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-16\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/crinetics-pharmaceuticals-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-16\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/crinetics-pharmaceuticals-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-16\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODg3MTkwMyM1NjgyMTEwIzIwODk4MTU=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODg3MTkwMyM1NjgyMTEwIzIwODk4MTU="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/crinetics-pharmaceuticals-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-16\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Crinetics Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/768741","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=768741"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/768741\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=768741"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=768741"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=768741"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}